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Purpose or Objective: to analyze possible clinical value of 
lymph flow visualization as the guide for irradiation of IMLN. 
 
Material and Methods: On the first stage of the study we 
combined data of 8 published studies that analyzed lymph 
flow from primary BC (4541 patients) after intra- peritumoral 
injection of nanosized 99mTc-colloids. Using this data we 
determined probability of lymph flow from BC of 
internal/central or lateral localization to IMLN. In 7 studies 
(4359 women) axillary staging was accompanied by biopsy of 
sentinel lymph nodes localized in internal mammary region. 
This data made it possible to estimate probability of IMLN 
metastatic invasion in relation with the status of axillary LN. 
At the final stage of the study we calculated probability of 
IMLN invasion by BC in 4 randomized and 2 observation 
studies that analyzed effect of IMLN irradiation on overall 
survival. Additionally, we tried to calculated possible 
additional gain in survival if patients from this 6 (4+2) trials 
would be treated according to lymph flow guided irradiation 
of IMLN. 
 
Results: According to results of 8 published studies lymph-
flow from lateral BC to IMLN was detected in 16% (727/4541), 
from internal/central lesions – in 35% (1589/4541).Evaluation 
of 7 studies (4359 women) showed that in patients with 
noninvolved axillary LN metastases in IMLN were revealed in 
7.8%, in patients with positive axillary nodes - in 38.1% cases. 
In all 6 studies that evaluated clinical value of IMLN 
irradiation, calculated probabilities of IMLN metastatic 
invasion in “high risk patients” didn’t exceed 10%. If IMLN 
irradiation would be performed only in patients with lymph 
flow to IMLN about 72.1%-76.8% of “high risk patients” would 
escape RT to IM region. In remained 23.2%-28.9% patients 
with visualized internal mammary sentinel lymph nodes their 
irradiation would improve overall survival from 1.6%-3.3% to 
6.9%-14.2%. 
 
Conclusion: visualization of lymph flow from breast cancer 
after intratumoral injection of 99mTc-nanocolloids make 
decision about irradiation of IMLN more precise and efficient. 
Irradiation of visualized IMLN can significantly (6.9%-14.2%) 
improved overall survival in this group of patients with BC. 
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Purpose or Objective: To assess the feasibility of 
Simultaneous Integrated Boost in Intensity Modulated 
Radiotherapy (SIB-IMRT) for breast cancer (BC) in the attempt 
to reduce the radiation treatment time. Results in terms of 
late toxicity and local control were compared with a control 
group (CG) of patients treated with 3-dimensional (3-D) 
conformal radiotherapy plus sequential boost. 
 
Material and Methods: MARA-2 was conceived as a single arm 
phase I-II trial. Patients with moderate-high risk BC were 
enrolled and treated with forward-planned IMRT technique. 
Whole breast and tumor bed received a total dose of 50 Gy 
and 60 Gy (10 Gy concomitant boost) in 25 daily fractions, 
respectively. In CG group, prescribed dose to the breast was 
50.4 Gy in 28 fractions with a sequential 10 Gy boost to the 
tumor bed in 4 fractions. Late skin and subcutaneous toxicity 
were evaluated using EORTC/RTOG scoring scale. 
 
Results: Four hundred and fifty one patients were included in 
our study (MARA-2: 321; CG: 130). Median follow up was 52 
months (range: 3-115). G1 and G2 late skin toxicities were 
acceptable without significant differences between the two 
groups. No G≥3 late skin toxicity was observed in MARA-2. At 
univariate analysis, late G1 and G2 subcutaneous toxicities 
were significantly higher in MARA-2 (p<0.001). 5-year G1 
subcutaneous late toxicity free-survival (LTFS) were 73.4% 
and 38.5% in CG and MARA-2, respectively; moreover, 5-year 
G2 subcutaneous LTFS were 96.5% and 80.0% in CG and MARA-
2, respectively. 5-year G3 subcutaneous LTFS was 0.9% in 
MARA-2 and 0% in CG, respectively. No differences were 
found in term of loco-regional control (LC) with a 5-LC of 
96.7% and 97.6% in CG and MARA-2, respectively (p=0.676). 
 
Conclusion: The use of SIB-IMRT technique in postoperative 
radiotherapy of BC allowed to reduce overall treatment time 
without significantly increasing the incidence of G>2 late 
effects. 
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Purpose or Objective: To evaluate the feasibility and 
toxicity profile in elderly women, with a diagnosis of early 
stage breast cancer, underwent to adjuvant hypofractionated 
Volumetric Modulated Arc Therapy (VMAT) and simultaneous 
integrated boost (SIB) after conserving surgery (CS).  
 
Material and Methods: Between September 2013 to March 
2015, 50 consecutive women with a diagnosis of early stage 
of breast cancer were treated with SIB-VMAT after CS in our 
Institution. Inclusion criteria were: age ≥ 65 years, pT1 -2 
disease, pN 0-1, no neoadjuvant chemotherapy, no-
metastatic disease. A dose prescription of 40.5 Gy in 15 
fractions was prescribed to the whole breast (PTVbreast) and 
an additional radiation dose of 48.5 Gy in 15 fractions to the 
tumour bed was prescribed (PTVboost). Hypofractionated 
treatment was purposed in patients with negative margins 
after surgery (> 1 mm). All patients were followed with 
periodic clinical evaluation. Acute toxicity were scored using 
EORTC/RTOG radiation morbidity score system. Both patient 
and physician recorded cosmetic outcome evaluation with a 
subjective judgment scale at the time of scheduled follow-
up. 
 
Results: Median follow-up was 20 months. At the time of the 
analysis, overall survival and local control rates were 100%. 
All patients completed the SIB-VMAT without interruptions. 
Acute skin toxicity was recorded as follow: grade 0 in 22 
patients (44%), grade 1 in 24 cases (48%), grade 2 in 4 
patients (8%). Regarding late adverse events, skin toxicity 
was registered as follow: grade 0 in 40 patients (80%), grade 
1 in 10 cases (20%). No toxicity ≥ grade 2 was registered. In 
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terms of cosmetic results, 99% and 1% of patients considered 
the result as good/excellent and as fair after RT, 
respectively. No patients had a poor cosmetic outcome. 
 
Conclusion: These results support the feasibility and good 
tolerability of SIB-VMAT in elderly patients with a diagnosis of 
breast cancer following CS with acceptable acute and late 
treatment-related toxicity. These preliminary results 
justified continuing the clinical study with the goal to 
establish the impact of hypofractionated SIB-VMAT in elderly 
patients with diagnosis of early stage breast cancer.  
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Purpose or Objective: To investigate the pathogenesis of 
peri-prosthesic capsule contraction (CCPP) related to post 
mastectomy radiotherapy in breast cancer patients 
undergoing breast reconstruction with heterologous material. 
 
Material and Methods: Patients developing (early or late) 
CCPP after breast reconstruction were enrolled in this study. 
CCPP was clinically evaluated by Baker score in order to 
define pain, rigidity, firmness and dislocation of implant. 
CCPP was analysed considering pathological aspect after sub-
total capsulectomy with anterior removal of peri-prosthesic 
capsule. Patients were split into two groups according to 
radiotherapy administration. Group 1 accounted for 
irradiated patients (50 Gy, 2 Gy per fraction on chest wall, 
using tangential field-in-field technique). Group 2 included 
not irradiated patients. Baker Score and microscopic 
observation (simil-synovial reaction, hyalinosis, vascular 
reaction, giant cells) of the two groups were compared by 
univariate and multivariate analysis. 
 
Results: Analysis was performed on 26 patients who 
developed CCPP (29 capsulectomy, because 3 bilateral) in the 
period between April 2012 and February 2015 (34 months). 
All patients developed CCPP within 1 year from first 
reconstructive surgery. Characteristics of both groups are 
reported in Table 1. 
 
Univariate analysis showed a positive association between 
Baker Score and radiotherapy (OR: 1.65), and hyalinosis and 
radiotherapy (OR: 1.2). Multivariate analysis confirmed 
association between CCPP and radiotherapy (OR: 17.9); 
chemotherapy (OR: 4.3) and hormone therapy (OR: 48.44) in 
terms of contraction grade and simil-synovial reactions 
respectively. 
 
Conclusion: Radiotherapy after breast reconstruction 
significantly influenced onset and severity of CCPP, although 
other variables contributed to CCPP multifactorial aetiology. 
In particular, hormone therapy and chemotherapy played a 
role in modifying capsular architecture. 
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Purpose or Objective: Evaluation of radiation- induced 
morbidity is routinely done as an integrated part of 
treatment response follow-up, and can be scored according 
to clinical assessment tools such as the CTCAE or LENT-SOMA. 
Objective measures in this evaluation would be valuable 
given their quantitative nature, facilitating comparison 
across cohorts and treatment institutions. High-frequency 
ultrasound (US) is a high-precision, objective tool to measure 
dermis thickness of the skin. We aimed to analyze dermis 
thickness in a cohort of women following radiotherapy (RT) 
for breast cancer with various grades of induration and 
edema. 
 
Material and Methods: The cohort was recruited from the 
DBCG HYPO/PBI RT protocols and comprised 15 women 
treated for early breast cancer during 2009–2013 with 
lumpectomy and RT 50 or 40 Gy +/- systemic therapy. 
Clinical morbidity follow-up of induration and edema was 
done at baseline and annually according to the LENT-SOMA 
scale. Dermis thickness was measured in mm using high-
frequency US. Points of measurement were 3 cm from the 
areola in four quadrants in both irradiated and contralateral 
non-irradiated breasts. Differences in mean dermis 
thicknesses were tested by two-tailed paired t-test. The US 
scanner utilized was a high-resolution 20 MHz DermaScan® C 
from Cortex Technology ApS. This device is optimized for 
recognizing structures at 60 µm, corresponding to tissue 
microstructures sized like collagenous fibres. 
 
Results: Median follow-up time was 3.0 years (range 1.0 – 
4.6). Overall, mean dermis thicknesses were 2.22 mm (1.78 -
2.66) in the irradiated (I) breast and 1.26 mm (95% CI: 1.08 - 
1.44) in the contralateral (C) breast. Mean difference 
between breasts was 0.96 mm (0.49 - 1.43, p<0.001). Dermis 
thickness was distributed in quadrants as follows: Lower 
lateral I: 2.62 (1.92 – 3.31) C: 1.11 (0.96 - 1.26), lower 
medial I: 2.64 (2.06 – 3.21) C: 1.45 (1.18 - 1.72), upper 
lateral I: 1.55 (1.33 – 1.78) C: 1.17 (1.01 – 1.34), upper 
medial I: 2.08 (1.49 – 2.67) C: 1.31 (1.09 – 1.53). In patients 
without clinical edema, the mean difference in dermis 
thickness for grade 1 induration was 0.35 mm (-0.46 - 1.16, 
p=0.21) and for grade 2 induration 0.71 mm (-0.01 - 1.43, 
p>0.05). In patients with clinical edema, only one patient had 
grade 1 induration (dermis thickness difference 1.34 mm). In 
